Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Laboratório Brasileiro de Biologia (LBB) is a pioneering Brazilian pharmaceutical company with a deep historical legacy in the production of immunobiologicals. Established in 1912, the company specializes in the development and manufacturing of vaccines, antitoxins, and hyperimmune serums. LBB is a key supplier of essential medicines in Brazil, including the tetanus toxoid and adult diphtheria-tetanus (dT) vaccines. The company maintains GMP-certified manufacturing operations in Rio de Janeiro, focusing on high-quality biological production to support national public health initiatives and the private healthcare sector. LBB remains one of the few private domestic entities in Brazil with the capability to produce complex biological products like toxoids and antisera.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Laboratorio Brasileiro de Biologia.